Ilic Milena, Ilic Irena
Department of Epidemiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia.
Student of Integrated Academic Studies for a Doctor of Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
J Public Health (Oxf). 2016 Jun;38(2):e63-7. doi: 10.1093/pubmed/fdv064. Epub 2015 May 20.
The aim of this descriptive epidemiological study was to analyze the mortality trend of prostate cancer in Serbia (excluding the Kosovo and Metohia) from 1991 to 2010.
The age-standardized prostate cancer mortality rates (per 100 000) were calculated by direct standardization, using the World Standard Population. Average annual percentage of change (AAPC) and the corresponding 95% confidence interval (CI) was computed for trend using the joinpoint regression analysis.
Significantly increased trend in prostate cancer mortality was recorded in Serbia continuously from 1991 to 2010 (AAPC = +2.2, 95% CI = 1.6-2.9). Mortality rates for prostate cancer showed a significant upward trend in all men aged 50 and over: AAPC (95% CI) was +1.9% (0.1-3.8) in aged 50-59 years, +1.7% (0.9-2.6) in aged 60-69 years, +2.0% (1.2-2.9) in aged 70-79 years and +3.5% (2.4-4.6) in aged 80 years and over. According to comparability test, prostate cancer mortality trends in majority of age groups were parallel (final selected model failed to reject parallelism, P > 0.05).
The increasing prostate cancer mortality trend implies the need for more effective measures of prevention, screening and early diagnosis, as well as prostate cancer treatment in Serbia.
这项描述性流行病学研究的目的是分析1991年至2010年塞尔维亚(不包括科索沃和梅托希亚)前列腺癌的死亡率趋势。
采用世界标准人口,通过直接标准化计算年龄标准化前列腺癌死亡率(每10万人)。使用连接点回归分析计算趋势的平均年度变化百分比(AAPC)及其相应的95%置信区间(CI)。
1991年至2010年期间,塞尔维亚前列腺癌死亡率呈显著上升趋势(AAPC = +2.2,95%CI = 1.6 - 2.9)。在所有50岁及以上男性中,前列腺癌死亡率呈显著上升趋势:50 - 59岁年龄组的AAPC(95%CI)为+1.9%(0.1 - 3.8),60 - 69岁年龄组为+1.7%(0.9 - 2.6),70 - 79岁年龄组为+2.0%(1.2 - 2.9),80岁及以上年龄组为+3.5%(2.4 - 4.6)。根据可比性检验,大多数年龄组的前列腺癌死亡率趋势是平行的(最终选定模型未能拒绝平行性,P > 0.05)。
前列腺癌死亡率上升趋势意味着塞尔维亚需要采取更有效的预防、筛查和早期诊断措施以及前列腺癌治疗措施。